Disclaimer:
DOK ROK
Pharmaceuticals & Healthcare GmbH
Registration No. HRB 38308 HB
Dr. Qais Aburok (M. Sc.)
Address
Carl-Severing-Straße 8
D – 28329 Bremen, Germany
M: +49 15203383276
E: contact@dokrok.com
www.dokRok.com
The planned placebo-controlled double-blind clinical study of SalvaRok:
Various studies in applied clinical research have provided concerning results concerning oral health, which is increasingly becoming a focal point of public health research. Researchers emphasize that elderly individuals, constituting 70{0db87290926490a23b6ab4078703ebe9d2213b02596285e6d3a260bb88493503} of those in need of care in outpatient and inpatient care facilities, possess worrisome oral health and represent a high-risk group. Periodontitis, therefore, is a common ailment. An anti-inflammatory diet plays a crucial role in maintaining healthy oral health. A healthy periodontium forms the fundamental basis for oral health. Moreover, periodontitis can be associated with systemic diseases in the rest of the body.
Treatment options for chronic inflammation of the periodontal tissues are limited, currently relying on mechanical treatment of periodontitis, involving the removal of biofilm and hard deposits on root surfaces. For probing depths greater than 5 mm, additional antibiotic administration is required. Due to the multifactorial nature of periodontal diseases, various approaches to combat inflamed periodontal tissues appear essential. SalvaRok® can yield additional therapeutic effects, particularly in restoring the balance of the oral microbiota by eliminating niches for periodontopathogenic microorganisms and preventing their growth. The immune response, which is excessively triggered during periodontitis and leads to genetic damage and tissue degradation, can be directed through dietary changes. Currently, conservative treatment provides insufficient evidence for therapy-related dietary recommendations, although individual micronutrients are offered as dietary supplements, some of which have been studied for their effectiveness in vitro and in vivo. However, neither dietary changes nor dietary supplements are integrated into treatments. The high-risk group mainly consists of seniors, who are almost entirely composed of multimorbid patients. For this high-risk group, consistent dietary changes cannot be guaranteed. Therefore, the supplementation of micronutrients is the only viable option. Targeted preventive micronutrient supplementation can help minimize inflammation, maintain the balance of the oral microbiota, prevent tissue degradation, and positively influence treatment success.
Currently, conservative periodontitis treatment provides insufficient evidence for therapy-related dietary recommendations, although individual micronutrients are offered as dietary supplements, some of which have been studied for their effectiveness in vitro and in vivo. A particular challenge lies in the fact that the high-risk group of periodontal diseases consists almost entirely of multimorbid patients. Therefore, supplementation of micronutrients must be associated with periodontitis patients.
Our planned placebo-controlled double-blind study will treat two groups with periodontal diseases of the high-risk group with either SalvaRok® or a placebo preparation over a period of 12 weeks. Subsequently, the groups will be compared, and the results will be statistically evaluated. The aim of this study is to test SalvaRok® for its effectiveness in terms of clinical parameters for pathological diagnosis and thus to improve oral health. SalvaRok® is not exclusively applicable to conservative periodontitis therapy but also acts as an antioxidant and DNA repair agent to improve oral flora. SalvaRok® supports the preservation of a range of metabolic processes and prevents the destruction of micronutrient and supramolecular structures.
Stay tuned and let us advise you!
Your Dok Rok Team